Literature DB >> 15486837

Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.

Mayfong Mayxay1, Maniphone Khanthavong, Niklas Lindegårdh, Siamphay Keola, Marion Barends, Tiengkham Pongvongsa, Ratsuda Yapom, Anna Annerberg, Samlane Phompida, Rattanaxay Phetsouvanh, Nicholas J White, Paul N Newton.   

Abstract

BACKGROUND: Recent clinical trials in the Lao People's Democratic Republic have demonstrated that chloroquine and sulfadoxine-pyrimethamine, which are national malaria treatment policy, are no longer effective in the treatment of uncomplicated Plasmodium falciparum malaria.
METHODS: A randomized comparison of 3 oral antimalarial combinations--chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine--with 42-day follow-up period, was conducted among 330 patients with acute uncomplicated falciparum malaria in southern Laos.
RESULTS: The 42-day cure rates, as determined by intention-to-treat analysis and adjusted for reinfection, were 100%, 97%, and 93% for the groups receiving artesunate plus mefloquine, artemether-lumefantrine, and chloroquine plus sulfadoxine-pyrimethamine, respectively. Of 8 patients receiving chloroquine plus sulfadoxine-pyrimethamine who experienced treatment failure, 6 had early treatment failure. The mean parasite clearance time was significantly longer in patients treated with chloroquine plus sulfadoxine-pyrimethamine (2.9 days; 95% confidence interval [CI], 2.8-3.0 days) than in those treated with artesunate plus mefloquine (2.07 days; 95% CI, 2.0-2.1 days; P<.001) and artemether-lumefantrine (2.08 days; 95% CI, 2.0-2.1 days; P<.001). Cure rates with artemether-lumefantrine were high despite low mean daily dietary fat intake (13.8 g; 95% CI, 12.5-15.1 g) and day 7 plasma lumefantrine concentrations (0.47 mu g/mL; 95% CI, 0.38-0.56 mu g/mL).
CONCLUSION: Oral artesunate plus mefloquine and artemether-lumefantrine are highly effective for the treatment of uncomplicated falciparum malaria in Laos.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486837     DOI: 10.1086/424512

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  43 in total

Review 1.  Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria.

Authors:  A A A Omari; C Gamble; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.

Authors:  Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 3.  Plasmodium falciparum Containment Strategy.

Authors:  V K Agrawal
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 4.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

5.  Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.

Authors:  Gabriel Carrasquilla; Clemencia Barón; Edwin M Monsell; Marc Cousin; Verena Walter; Gilbert Lefèvre; Oliver Sander; Laurel M Fisher
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

6.  Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.

Authors:  Pauline Byakika-Kibwika; Mohammed Lamorde; Harriet Mayanja-Kizza; Concepta Merry; Bob Colebunders; Jean-Pierre Van Geertruyden
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

7.  A phase III, randomized, non-inferiority trial to assess the efficacy and safety of dihydroartemisinin-piperaquine in comparison with artesunate-mefloquine in patients with uncomplicated Plasmodium falciparum malaria in southern Laos.

Authors:  Mayfong Mayxay; Sommay Keomany; Maniphone Khanthavong; Phoutthalavanh Souvannasing; Kasia Stepniewska; Tiengthong Khomthilath; Siamphay Keola; Tiengkham Pongvongsa; Samlane Phompida; David Ubben; Neena Valecha; Nicholas J White; Paul N Newton
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

8.  Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.

Authors:  Stephan Ehrhardt; Christian G Meyer
Journal:  Ther Clin Risk Manag       Date:  2009-10-12       Impact factor: 2.423

9.  A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire.

Authors:  Offianan A Toure; Louis K Penali; Jean-Didier Yapi; Berenger A Ako; Walamtchin Toure; Kali Djerea; Genevieve O Gomez; Oyewole Makaila
Journal:  Malar J       Date:  2009-07-03       Impact factor: 2.979

Review 10.  Safety profile of Coartem: the evidence base.

Authors:  Catherine Falade; Christine Manyando
Journal:  Malar J       Date:  2009-10-12       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.